It has been recently demonstrated, by plasma analysis of European EPIC cohort patients, that the combination CA19-9 and ApoA2 may improve detection of pancreatic cancer compared to CA19-9 alone (Honda et al., 2019). This evidence concerns the gene APOA2 and pancreatic neoplasm.